Tempus AI’s Post

NECTIN4 amplification predicts response to Enfortumab vedotin in mUC! It occurs frequently across solid tumors (app. 25% of mUC) potential tumor-agnostic biomarker for NECTIN4-targeting therapies! Happy to share our poster K17

❓Which 2L treatment option would you recommend for patients w/ #mBC & an ESR1 mutation? Challenge yourself w/ our interactive patient case video series with MCQs & clickable resources! In Episode 1/2 Dr Elisa Agostinetto explores the intricacies of ER+ mBC. Interactive insights, challenging questions, and clickable resources await you on this informative journey! ➡ https://lnkd.in/d5qK2e4F Clinical Takeaways: 🔸 Tumor characteristics influence treatment decisions. 🔸 Liquid biopsy, especially ctDNA analysis, aids in detecting #ESR1 mutations with sensitivity. 🔸 #Elacestrant, the first FDA-approved oral #SERD (Jan 2023), offers a promising choice. 🔸 Oral SERDs show potential in monotherapy and combo treatments with CDK4/6, PI3K, and AKT inhibitors. #MedEd #bcsm #patientcare

Liquid Biopsy Genomic testing, a cornerstone of precision medicine, has revolutionized cancer treatment by enabling personalized care. However, one major hurdle remains - cost. Early detection and tailored treatments are key to improving outcomes, yet the high cost of genomic testing limits its accessibility. A recent article by MedPage Today discusses the ongoing cost issue revealing that insurance and out-of-pocket expenses significantly influence oncologists' decisions in using genomic testing. This is a stark reminder of the work still needed to make these life-saving technologies accessible to all. This is exactly what we are trying to change at JaxBio by pioneering affordable liquid biopsy technologies to drastically reduce costs from thousands to mere tens of dollars. This is just the tip of the iceberg in a market poised for exponential growth and I am proud to lead a company that is tackling the challenge head on. Imagine a world where early cancer detection is not a luxury but a standard - a world where every patient receives the care they deserve. This should not be a pipedream but a reality. #HealthcareInvestment #Innovation #NextGenSequencing

What a great video from Cholangiocarcinoma Foundation, D2 Creative and Luminations about cancer biomarkers. Kudos for encouraging medical and clinical trial literacy for patients and their care takers! #biomarkers #clinicaltrials #cancer #oncology

Cool little explainer video about the importance of #biomarkers in #cancer. #NGS #precisionmedicine #precisiononcology

Check out the NACE On-Demand Course: Resistance to Targeted and Immunotherapy in NSCLC. As the number of targetable genetic alterations identified in NSCLC has increased, so has the number and type of approved targeted agents, with some of these agents and ICIs being integrated further into treatment at earlier stages of disease, including adjuvant therapy. In concert with increased use of these therapies has been discovery of resistance mechanisms that limit continued progress against NSCLC. In this webcast, Sandip Patel, MD, discusses the mechanisms of acquired resistance to targeted therapies and ICIs in patients with NSCLC, recommended testing for specific biomarkers associated with resistance to first-line therapies, and a case-based review of evidence-based treatment plans for sequencing agents to optimize response in the presence of acquired resistance in patients with NSCLC. Click here to start the course: https://bit.ly/46jhSN3. #NACE #OnDemand #NSCLC #Webcast

Overall survival results were published from KEYNOTE-564.  This was a phase III trial comparing 1 year of adjuvant pembrolizumab vs placebo in high risk clear cell renal cell carcinoma after surgical resection.  The trial demonstrated a HR of 0.62 (0.44-0.87; p=0.005).  Another positive from this data is that the survival curves continue to separate after completion of pembrolizumab, showing that adjuvant treatment does not only delay time to recurrence, and has a long-term benefit.   Overall survival at 48 months was 91.2% in the pembrolizumab group and 86.0% in the placebo group, so around 1 in 20 patients benefited from the addition of this therapy.  It is important not to extrapolate these results to a lower-risk population, as that may be one of the reasons why adjuvant nivoluamb failed in renal cell carcinoma (CheckMate 914).  Given the clear overall survival benefit, we should be giving 1 year of pembrolizumab in all high risk patients after resection. #keytruda #kidneycancer https://lnkd.in/e9yVhiV8

Drug extravasation in cancer patients - Full Text... "This comprehensive review explores the pathophysiology, incidence, risk factors, clinical presentation, diagnosis, prevention strategies, management approaches, complications, and long-term effects of extravasation in cancer patients" Pham and Tsunoyama (2024).

Genomic testing enables personalized cancer care, and early detection further improves management. However, despite these benefits, challenges persist, particularly regarding cost. A recent article by MedPage Today highlights this issue. A national survey of 1,049 oncologists revealed that about half consider insurance and out-of-pocket expenses "very important," while another 30% deem them "somewhat important.” The article's findings, based on 2017 data, show that while circumstances have evolved over six years, cost discussions remain crucial. Stephen Grubbs, MD, VP of Care Delivery, American Society of Clinical Oncology (ASCO), echoes this sentiment. Insurance coverage and out-of-pocket expenses significantly influence oncologists' decisions to use genomic testing for treatment. Liquid biopsies use plasma-based Next Generation Sequencing (NGS). Our innovative approach to cost reduction at Jaxbio will make liquid biopsy more accessible to everyone. With our unique technology we aim to lower testing costs, with a target price of $30, compared to the $3200 cost of 30X Whole Genome Methylation Sequencing. Link to the article: https://lnkd.in/euB7n8uE Learn more about Jaxbio: www.jaxbio.com #NGS #LiquidBiopsies #PrecisionMedicine

#HCC #LAG-3 #immunomodulatory #tumor microenvironment 📗 Topic: Shedding light on the role of LAG-3 in hepatocellular carcinoma: unraveling immunomodulatory pathways 🔖 This narrative review aims to delve into the full spectrum of LAG-3 signaling in HCC, with the goal of a better understanding of the pathophysiological and immunological basis of its use to arrest HCC growth and development. ✔ Understanding LAG-3 signaling ✔ The immunologic basis of anti-LAG-3 therapies ✔ The clinical landscape of LAG-3-targeted hepatocellular carcinoma therapy 👉 Read more: https://lnkd.in/gUHbXF2H Welcome to share it with your colleagues! GEORGIOS GERMANIDIS